MPP is excited to be participating in the 24th International AIDS Conference in Montreal and virtually!
Please see below MPP’s in-person participation in some key sessions. You can also come visit our booth and take our quiz to receive prizes.
Friday 29 July, 07:45-08:45 EDT, Room 517c/Channel 5
MPP Policy and Advocacy Manager Sébastien Morin participating in roundtable on “PrEP for 2030 — what will it take to scale?” during satellite session on “PrEP-ing for 2030: Why optimization and scale-up of the PrEP service and product mix is critical to addressing unmet PrEP need and supporting effective use towards 2030 HIV prevention goals” – More information
Friday 29 July, 16:30-18:00 EDT, Room 518/Channel 10 – Satellite session co-hosted by MPP
MPP Executive Director Charles Gore co-chairing MPP/IAS satellite session on “Accessing long-acting HIV prevention and treatment innovations: Landscape, service delivery, and pathways to affordability” – More information
Friday 29 July, 18:15-19:45 EDT, Room 517a/Channel 3
Charles Gore facilitating a panel discussion in the session “HIV and Viral Hepatitis: integrating programmes and financing to accelerate achievement of twin goals to eliminate HIV and viral hepatitis by 2030” – More information
Saturday 30 July, 14:15-15:15 EDT, Room 511/Channel 7
MPP Head of Policy and Advocacy Esteban Burrone presenting on “Strategies to enhance equitable health product roll out in low- and middle-income countries” during symposium session on “Equitable roll out of health products: What will it take?” – More information
Saturday 30 July, 15:00-16:00 EDT – AfroCAB stand, Global Village
Sébastien participating in community dialogue on “MPP ViiV healthcare agreement what next?”
Sunday 31 July, 9.30-10.30 EDT – UNAIDS meeting room 519b
Join online
Charles Gore participating in discussion on the mRNA technology transfer hub programme on sustainability and country engagement
mRNA tech transfer hub programme and country engagement
The mRNA technology transfer hub and spoke model aimed at empowering low- and middle-income countries (LMICs) through sharing knowledge, building capacity, and creating a network of collaboration is well on track to deliver in the Covid-19 space. It is now indisputable that to face future pandemics and ensure vaccine equity, LMICs need to be part of the solution. Sustainability is key, other vaccines e.g. HIV or TB, will be essential along with strong global and country support.
The session will provide a comprehensive view of the mRNA technology hub programme and initiate discussion on building engagement with countries towards ensuring integration and uptake of vaccines in their countries and regions.
Speakers
· Matt Kavanagh, Deputy Executive Director a.i. UNAIDS
· Dr Soumya Swaminathan, Chief Scientist WHO
· Prof Petro Terblanche, CEO Afrigen
· Charles Gore, Executive Director, Medicines Patent Pool
Followed by a moderated discussion on building country engagement.
Monday 1 August 13:00-14:00 EDT, Room 220d/e / Channel 1
Charles Gore participating in panel discussion during Prime session on “Health equity for all.” – More information
Tuesday 2 August, 10:30-11:30 EDT, Room 516/Channel 6
Sébastien Morin presenting on “Quantifying the health and economic impact of voluntary licensing of HIV medicines in low- and middle-income countries: Putting numbers on additional uptake, deaths averted, and money saved by MPP licences” during oral abstract session on “Achieving sustainability in the HIV response: Thinking differently!” – More information
MEET MPP at our booth #1007 in the Exhibition Area.
Visit our booth #1007 in the Exhibition Area. Take our quiz and win a prize!
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.